Considerations for the development of biologics by virtual companies – April 22 2021
Click HERE to register for a LIVE presentation from industry expert Dr. Jonathan Dempsey on Considerations for the Development of Biologics by Virtual Companies.
Abstract includes:
The development and commercialization of biological medicines is a complex and time-consuming process which requires specific expertise and skills across a wide range of disciplines.
In order to maximize the future value of your molecule, enhance its successful transition to clinical manufacturing and to ensure the timeliest passage to clinical testing we have determined several key considerations for the success of virtual biopharma companies.
We present our experiences, specifically applicable, for small and virtual companies who are developing biologics. Subjects such as provision of material for early evaluations, defining criteria for the selection and management of manufacturing partners, assessing and choosing development technologies and building development plans will be discussed. Planning, budgeting and milestone setting, specifically in the context of raising finance will also be covered
Finally, we will define our optimal pathway to the manufacture of your first clinical batch and propose key tasks, funding requirements and milestones to enhance success.
With almost thirty years’ experience in the development and manufacture of biologics, with companies such as Lonza Biologics, Cambridge Antibody Technology and Invitrogen, Jon has deep knowledge in the Chemistry, Manufacture and Control for biologics and in the application of innovative technologies impacting this field. Jon also offers specialist expertise in cell line development, upstream process development, process intensification and cell culture medium development.
